HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

C&D Powers Into Acne Market Acquiring Hero Cosmetics, Maker Of Top-Selling Mighty Patch

Executive Summary

Church & Dwight agrees to buy Hero Cosmetics, maker of acne and skin care patches and topical products, for $630m, adding leading US acne patch brand to its “power brand” lineup. Mighty Patch is among more-than 30 products Hero manufactures and markets.

You may also be interested in...



Church & Dwight Improves On Meeting Demand, But Doesn’t Deliver Better Full-Year Forecast

Lowers full-year forecast for reported sales growth to 4% to 5% from an earlier estimate of 5% to 8% despite improving to 89% on meeting demand during the April-June period from 80% during Q1.

C&D Expands Oral Care Portfolio, Acquires TheraBreath Mouthwash Brand In Latest Deal

Church & Dwight anticipates 15% growth for TheraBreath mouthwash brand in 2022 on larger sizes and wider distribution, especially outside US. It plans to acquire the firm for around $580m cash and close the deal before end of year

PCPC Working To Ensure State EPR Programs Are ‘Least Onerous As Possible’

The Personal Care Products Council is engaging on state legislation for extended producer responsibility programs, which impose the cost of recycling plastic materials on manufacturers. Emerging bills to prohibit use of the ‘chasing arrows’ recycling symbol on consumer packaging also have the trade group’s attention.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS152896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel